Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methodology and quality assurance practices in performing anti-extractable nuclear antigen (ENA) analysis: an EFLM report on an international survey.

Clinical chemistry and laboratory medicine·2026
Same author

Patient-Reported Outcomes in Clinical Trials of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Exome sequencing directly implicates 68 genes in inflammatory bowel disease.

medRxiv : the preprint server for health sciences·2026
Same author

Improvement in Health-Related Quality of Life in Patients with Moderate to Severe Crohn's Disease Treated with Risankizumab vs Ustekinumab in the Phase 3B SEQUENCE Study.

The American journal of gastroenterology·2026
Same author

Faecalibacterium prausnitzii EXL01 for the Maintenance of Steroid-induced Clinical Response or Remission in Patients with Crohn's Disease: a first in human trial.

Nature communications·2026
Same author

Efficacy and safety of ABBV-154 in patients with moderately to severely active Crohn's disease: a phase 2b, randomized, double-blind, placebo-controlled trial.

Crohn's & colitis 360·2026

Related Experiment Video

Updated: Jul 17, 2026

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling.

Marie-Alice Meuwis1, Marianne Fillet, Pierre Geurts

  • 1Laboratory of Clinical Chemistry, GIGA Research, CHU, University of Liège, B34, 4000 Liège, Belgium.

Biochemical Pharmacology
|January 30, 2007
PubMed
Summary

Researchers identified novel protein biomarkers for inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis. These markers, PF4 and Hpalpha2, show promise for improving early diagnosis and classification of these chronic gastrointestinal conditions.

Related Experiment Videos

Last Updated: Jul 17, 2026

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

Area of Science:

  • Gastroenterology and Immunology
  • Biomarker Discovery
  • Proteomics

Background:

  • Inflammatory bowel diseases (IBD), encompassing Crohn's disease and ulcerative colitis, are chronic, multifactorial gastrointestinal disorders.
  • Current diagnosis relies on non-specific clinical, endoscopic, radiological, and histological criteria, highlighting the need for novel diagnostic markers.
  • Understanding the etiology and improving classification of IBD are critical for patient management.

Purpose of the Study:

  • To identify novel protein biomarkers in serum for the early diagnosis and classification of IBD.
  • To evaluate the diagnostic potential of identified biomarkers using advanced analytical techniques.
  • To explore the utility of SELDI-TOF-MS and multivariate statistical methods in biomarker discovery for IBD.

Main Methods:

  • Serum samples from 120 patients (30 Crohn's disease, 30 ulcerative colitis, 30 inflammatory controls, 30 healthy controls) were analyzed using Surface Enhanced Laser Desorption Ionization-Time of Flight-Mass Spectrometry (SELDI-TOF-MS).
  • Univariate and multivariate statistical methods, including multiple decision trees algorithms, were employed for data analysis and biomarker selection.
  • Potential biomarkers were identified using mass spectrometry and antibody-based methods, with validation through classical detection techniques for specific markers.

Main Results:

  • SELDI-TOF-MS analysis coupled with multivariate statistical methods identified potential protein biomarkers differentiating IBD patient groups.
  • Four potential biomarkers (PF4, MRP8, FIBA, and Hpalpha2) were identified, demonstrating significant diagnostic value.
  • Multivariate models achieved a minimum of 80% sensitivity and specificity in classifying patient samples, indicating high diagnostic accuracy.
  • Two identified biomarkers, PF4 and Hpalpha2, were successfully detected in patient sera using conventional methods.

Conclusions:

  • SELDI-TOF-MS technology and decision tree algorithms are effective tools for protein biomarker pattern analysis in IBD.
  • The identified biomarkers, particularly PF4 and Hpalpha2, hold significant potential for improving the classification and understanding the etiology of IBD.
  • Further research into these biomarkers could lead to enhanced diagnostic strategies for Crohn's disease and ulcerative colitis.